Preservation and Transfer of Hepatitis B Virus Immunity After Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Adult Sickle Cell Disease Patients (Protect Study)

Sickle cell disease (SCD) patients ending with mixed mononuclear chimerism after non-myeloablative HSCT with alemtuzumab/TBI conditioning will probably preserve their immune response to vaccinations administered prior to the transplantation and will therefore not need to be revaccinated. Furthermore, SCD patients after haploidentical HSCT might benefit from adoptive transfer of immunity from their donors.
To test the first hypothesis, patients undergoing alemtuzumab/TBI HSCT will be vaccinated with a hepatitis B virus (HBV) vaccine before the transplant. To test the second hypothesis, haploidentical and matched related donors will be vaccinated prior to stem cell donation against HBV. Neither the patient nor the donor may previously have been immunized against HBV in all cohorts. Post-transplantation, the investigators will be able to evaluate whether SCD patients preserve their pre-transplant immune response in the post-transplantation period. Furthermore, the investigators will determine whether donors transfer their immunity to HSCT recipients with SCD disease.

Start Date08 Jun 2021

Sponsor / Collaborator

Academic Medical Center University of Amsterdam

NCT04326803

/ Unknown statusPhase 4IIT

Hepatitis B Virus (HBV) Infection in Haitian Immigrants in Chile: Determination of HBV Genotypes, Viral Escape Mutants and Host Factors Influencing Response to Vaccination

International migration to Chile has sharply increased since 2010. Particularly, Haitian migration now totals approximately 200.000 people. Preliminary results show a high prevalence of hepatitis B infection in this population. Approximately 35% of adult Haitian migrants in Chile have been exposed to hepatitis B infection. In this study the investigators aim to study the clinical and molecular characteristics of this infection and also to assess the serological response to an accelerated schedule of hepatitis B vaccination (0, 1 and 2 months).

Start Date01 Jun 2020

Sponsor / Collaborator

Pontificia Universidad Católica de Chile

NCT04398706

/ CompletedPhase 2

Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants

Primary objectives:
* To assess the safety profile of each SP0202 formulation and Prevnar 13 in toddlers and infants (after each and any injection).
* To assess the immune response (serotype specific IgG concentration) of the SP0202 formulations and Prevnar 13 1 month after the administration of one dose in toddlers (Groups 1-4)
* To assess the immune response (serotype specific IgG concentration) of the SP0202 formulations and Prevnar 13 1 month after the administration of 3 doses in infants (Groups 5-8)
* To assess the immune response (serotype specific IgG concentration) of the SP0202 formulations and Prevnar 13 1 month after administration of a 4-dose schedule in infants (Groups 5-8)
Secondary objectives:
* To assess the immune response (serotype specific OPA titer) of the SP0202 formulations and Prevnar 13 1 month after the administration of one dose in toddlers (Groups 1-4)
* To assess the immune response (serotype specific OPA titer) of the SP0202 formulations and Prevnar 13 1 month after the administration of 3 doses in a subset of infants (Groups 5-8)
* To assess the immune response (serotype specific OPA titer) of the SP0202 formulations and Prevnar 13 1 month after administration of a 4-dose schedule in a subset of infants (Groups 5-8)
* In toddlers: to describe the Ab responses against Pentacel antigens before and 1 month following injection of Pentacel
* In infants: to describe the Ab responses against antigens of the routine pediatric vaccines (Pentacel, RotaTeq, ENGERIX-B, M-M-RII, and VARIVAX) when administered concomitantly with either SP0202 or Prevnar 13 (at pre-Dose 1 (as applicable) for RotaTeq, Diphteria, Tetanus and Pertussis antigens; at PD3 for ENGERIX-B, RotaTeq, and Pentacel; at PD4 for M-M-RII and VARIVAX])

Start Date22 May 2020

Sponsor / Collaborator

Sanofi Pasteur SA

100 Clinical Results associated with Hepatitis B vaccine(GlaxoSmithKline Plc)

100 Translational Medicine associated with Hepatitis B vaccine(GlaxoSmithKline Plc)

100 Patents (Medical) associated with Hepatitis B vaccine(GlaxoSmithKline Plc)

1,604

Literatures (Medical) associated with Hepatitis B vaccine(GlaxoSmithKline Plc)

01 Oct 2026·INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

EVOLVE-HBV: A cross-sectional study of HBV seroepidemiology in a rural population in South Africa

Article

Author: Olivier, Stephen ; Sukali, Gloria ; Siedner, Mark J ; Msomi, Nokukhanya ; Martyn, Emily ; Wong, Emily B ; Iwuji, Collins ; Upton, Janine ; Herbst, Kobus ; Delphin, Marion ; Ording-Jespersen, Gregory ; Mazibuko, Lusanda ; Matthews, Philippa C ; Hanekom, Willem A ; Smit, Theresa ; Ndung'u, Thumbi ; Ellapen, Malcolm ; Naidoo, Vasudevan G ; Gareta, Dickman ; Gunda, Resign ; Baisley, Kathy ; Anderson, Motswedi ; Khoza, Thandeka ; Waddilove, Elizabeth ; Maponga, Tongai G ; Mthethwa, Lulama

OBJECTIVES:

The "EVOLVE" study set out to investigate the population prevalence of hepatitis B virus (HBV) infection, immunity, and treatment eligibility in a rural South African setting.

METHODS:

We tested plasma samples from 2200 participants in a population-based study in KwaZulu-Natal, of whom 50% were living with human immunodeficiency virus, for HBV surface antigen (HBsAg), HBV core antibody, and HBV surface antibody. For samples testing HBsAg-positive, we quantified alanine aminotransferase (ALT) and HBV deoxyribonucleic acid (DNA) viral load. We evaluated demographic and clinical correlates of HBV biomarkers, explored the geographical distribution of HBsAg, and assessed HBV treatment eligibility.

RESULTS:

Weighted HBV infection prevalence was 10.4% (95% confidence interval [CI] 9.0-12.1%). Evidence of HBV exposure and clearance was found in 34.9% (95% CI 32.4-37.5). Overall prevalence of vaccine-mediated HBV immunity was 8.9% (95% CI 7.5-10.4%), but among the subgroup born between 2000 and 2005 (after the HBV vaccine was implemented), this increased to 20.2% (95% CI 15.8-25.4). Infection prevalence was highest in the southern part of the region. Over 60% of individuals testing HBsAg-positive met treatment eligibility criteria.

CONCLUSION:

Prevalence of HBV in this setting is high, while vaccine-mediated immunity is low. These data highlight a pressing need for the scale-up of interventions to support progress toward elimination targets.

01 Jul 2026·PROTEIN EXPRESSION AND PURIFICATION

Comparison of the efficacy of cell wall disruption methods for Saccharomyces cerevisiae INVSc1 cells expressing Toxoplasma gondii recombinant ROP6 protein

Article

Author: Döşkaya, Mert ; Döşkaya, Aysu Değirmenci ; Kantarcı, Ayşe Gülten ; Can, Hüseyin ; Gürüz, Adnan Yüksel ; Gül, Ceren ; Ovayurt, Tolga ; Karakavuk, Tuğba ; Yavuz, İrem ; Erel Akbaba, Gülşah ; Akbaba, Hasan ; Erkunt Alak, Sedef ; Kaplan Mansuroğlu, Seren ; Karakavuk, Muhammet ; Ün, Cemal ; Köseoğlu, Ahmet Efe ; Gül-Mete, Aytül

Toxoplasma gondii infects both humans and animals, causing severe clinical manifestations. Due to the lack of a safe vaccine, the development of a safe and effective vaccine against toxoplasmosis remains a significant need. Saccharomyces cerevisiae is a well-established recombinant protein expression system with Generally Recognized as Safe status. It supports post-translational glycosylation and is employed in several licensed vaccines, including hepatitis B (Engerix-B), human papillomavirus (Gardasil), and malaria (Mosquirix). Recombinant T. gondii proteins expressed in S. cerevisiae have been explored for use in vaccine formulations. However, cell disruption during downstream processing presents a major challenge due to the robust cell wall of yeast. In our previous work, T. gondii recombinant ROP6 protein was successfully expressed in S. cerevisiae INVSc1 cells for use as a vaccine antigen, and cell disruption was performed using a microfluidizer. In this study, we compared the efficiency of four disruption methods (microfluidizer, acid-washed glass beads, liquid nitrogen, and Y-PER reagent) for releasing recombinant protein. The results demonstrated that the microfluidizer and acid-washed glass bead methods achieved superior cell wall disruption efficiency, making them suitable for large-scale processing. The liquid nitrogen method caused excessive protein degradation and presents safety and scalability challenges. Although Y-PER reagent yielded lower amounts of rROP6 protein compared to microfluidizer and acid-washed glass bead methods, it provided good protein stability by reducing multimerization and degradation and offered operational simplicity. Overall, the choice of disruption method should be guided by the target protein's characteristics, production scale, and cost considerations to optimize yield and stability.

02 Jun 2026·JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Hepatitis B

Review

Author: Lok, Anna S. ; Jeng, Wen-Juei ; Yip, Terry Cheuk-Fung

Importance:

Hepatitis B virus (HBV) infection affects an estimated 254 million people worldwide and causes approximately 1.1 million deaths annually. In 2022, there were approximately 1.2 million new HBV infections worldwide and 14 000 in the US.

Observations:

HBV is a DNA virus transmitted through percutaneous or mucosal exposure to infected blood, semen, or body fluids. Mother-to-child transmission, which is the principal cause of chronic HBV infection globally, occurs in 70% to 90% of infants born to mothers who are hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive and in 5% to 20% of those born to HBsAg-positive/HBeAg-negative mothers. However, HBV vaccination and administration of hepatitis B immune globulin within 12 to 24 hours of birth prevent approximately 94% of perinatal infections, and adding antiviral therapy in pregnant women with high HBV DNA reduces transmission to less than 1%. Although universal birth-dose HBV vaccination is the most effective strategy for eliminating HBV infection, global birth-dose HBV vaccine coverage was only 45% in 2024. The risk of developing chronic infection (HBsAg positive for more than 6 months) is 90% if HBV infection occurs during infancy, 30% in children aged 1 to 5 years, and less than or equal to 5% in immunocompetent adolescents and adults. HBV infection is diagnosed by serologic testing: HBsAg indicates ongoing infection, antibody to HBsAg indicates immunity, and antibody to hepatitis B core antigen indicates ongoing or past infection. Serum HBV DNA levels quantify virus-replication activity. Assessment of liver inflammation and fibrosis with alanine aminotransferase (ALT) and noninvasive tests such as Fibrosis-4 index and liver elastography guide treatment decisions. Chronic HBV infection may progress to cirrhosis and hepatocellular carcinoma (HCC); the 5-year cumulative risk of cirrhosis is 8% to 15% in untreated chronic HBV infection, and annual HCC incidence is 3% to 5% among patients with cirrhosis. Antiviral therapies—pegylated interferon alfa and nucleos(t)ide analogues (entecavir or tenofovir)—suppress HBV DNA replication and reduce the risk of HCC by approximately 50%. Antiviral treatment is recommended for all patients with chronic HBV and cirrhosis and for those without cirrhosis who have high HBV DNA with elevated ALT or significant inflammation/fibrosis. Patients at high risk of HCC should undergo surveillance with ultrasonography and alpha-fetoprotein testing every 6 months.

Conclusions and Relevance:

HBV infection causes approximately 1.1 million deaths annually worldwide. Universal HBV vaccination, particularly birth-dose administration, is the most effective strategy to prevent HBV infection. Among patients with HBV infection, antiviral therapy decreases progression to cirrhosis and liver failure and reduces the risk of HCC.

News (Medical) associated with Hepatitis B vaccine(GlaxoSmithKline Plc)

27 Mar 2026

·www.fiercepharma.com

Fierce Pharma Asia—Takeda’s $1.3B reorg; India’s GLP-1 floodgates; Gilead’s $2.2B buy of a China NewCo

Takeda's $1.3 billion restructuring plan, semaglutide generic launches in India and Gilead's $2.2 billion Ouro acquisition made our news this week. Takeda is launching a restructuring, targeting nearly $1.3 billion in annual savings. Generic versions of Novo Nordisk's semaglutide reached India in chaotic fashion. Gilead Sciences is paying up to $2.2 billion to purchase a Chinese "NewCo." And more.1. Takeda targets $1.3B in cost savings in further restructuringTakeda is launching another round of restructuring, aiming to achieve 200 billion Japanese yen ($1.26 billion) in annual gross savings by its 2028 fiscal year. Resources will be reallocated to support upcoming launches, late-stage programs and strategic technology investments. To achieve increased efficiency, the company expects to incur 150 billion yen in restructuring expenses in fiscal 2026. 2. With Novo's semaglutide going off patent, Indian drugmakers set to launch their cheaper genericsGenerics to Novo Nordisk’s semaglutide have launched in India. More than 10 brands have launched online, and shortages have already happened despite inventory build-ups by companies, according to a March 26 note by Jefferies. For injectable versions, the monthly prices range between 1,290 rupees ($13.7) to 4,500 rupees ($47.8). “Companies are testing the waters with demand and supply, and they expect the market to settle down in the next few months,” Jefferies’ analysts said.3. Gilead's $2.2B Ouro buyout delivers autoimmune T-cell engager, new purpose for GalapagosGilead Sciences is paying $1.675 billion upfront for Ouro Medicines, a “NewCo” built on ex-China rights to a BCMAxCD3 T-cell engager from China’s Keymed Biosciences and funding from GSK and Monograph Capital. Known as gamgertamig, or OM336, the drug is being studied for autoimmune disorders. Gilead is planning for its partner Galapagos to essentially absorb Ouro.4. Novartis joins Lilly, AZ in China expansion with $480M commitment to boost manufacturing, R&DNovartis said it will invest 1.5 billion yuan ($220 million) to upgrade its manufacturing facility in Beijing and will spend another 1.8 billion yuan to initiate a second phase of its Shanghai R&D campus. “China is crucial to Novartis’ long-term development and innovation,” CEO Vas Narasimhan said at the 2026 China Development Forum.5. Dizal's Zegfrovy clinches landmark phase 3 win in NSCLC subtype, setting up challenge to J&J's RybrevantA global phase 3 trial of Dizal’s Zegfrovy has met its primary endpoint of progression-free survival in first-line EGFR exon 20-mutated non-small cell lung cancer, the Chinese biotech announced. The oral drug—as a monotherapy—beat chemo where Johnson & Johnson’s injectable Rybrevant achieved in combination with chemo. 6. Novo Nordisk prepares to go global as triple-G prospect passes midphase diabetes test in ChinaThe United Laboratories, licensor of Novo Nordisk’s GLP-1/GIP/glucagon triple agonist, reported a Chinese midphase win against semaglutide in Type 2 diabetes. After 24 weeks of once-weekly injections, levels of HbA1c fell up to 2.16% in the UBT251 cohorts, compared to declines of 1.77% for semaglutide. Novo plans to start a global phase 2 trial in diabetes this year.Other News of Note: 7. Biogen pays $20M upfront to tap into Alteogen's subQ delivery tech8. Massive class action seeking RICO penalties against Takeda, Lilly presses forward with SCOTUS order9. Innovent delivers first year of net profit amid growing sales, global partnerships (release)10. InnoCare achieves profitability for the first time thanks to 2 BD deals (release)11. Hengrui posts 13% annual revenue growth, but quarterly profit misses forecasts (Reuters)12. Sino Biopharm touts 26% sales growth from innovative drugs (release)13. Innovent sees path to China approval after eye disease drug matches Eylea in phase 314. WuXi Bio's record number of new projects in 2025 leaned heavily on US clients15. Akeso advances oncology strategy as revenue jumps 44% (release, PDF)16. Shionogi pays Apnimed $100M for joint venture to awaken sleep disorder dream17. BrightGene's oral dual agonist sees up to 8% weight loss at 8 weeks in slice of early data18. GSK partners with Shanghai Pharma to bring hepatitis B vaccine back to China (Yicai)

Phase 3AcquisitionClinical ResultVaccinePhase 2

14 Jan 2026

·www.biospace.com

JPM26: Sanofi’s CEO Keen To Buy the Dip as Vaccine Rhetoric Impacts Short-Term Sales

iStock, nito100 Buying vaccine biotech Dynavax was an easy choice for Sanofi despite antivaccine moves by the Trump administration. “It’s a good time to do vaccine BD and M&A,” according to Sanofi CEO Paul Hudson. While vaccine sentiment is suffering amid the Trump administration’s rhetoric, Hudson says he’s playing the long game with Sanofi’s acquisition of Dynavax . “With the uncertainty, if you’re a short-term thinker, you don’t move. If you’re a long-term thinker—which is what we have to be—then there are less people to compete against to make acquisitions,” Hudson told reporters at a media breakfast in San Francisco on day three of the J.P. Morgan Healthcare Conference. To end 2025, Sanofi offered $2.2 billion to buy Dynavax. The center of that deal is the hepatitis B vaccine Heplisav-B. That the vaccine is for adults could help Sanofi overcome some of the vaccine hesitancy that is rising, particularly in America, Hudson said. “We know that the sensitivities are less in the adult context.” And it was those sensitivities that set the stage for the French drugmaker to pay what Hudson called an “appropriate price” for Dynavax. Elsewhere on the company’s business development (BD) bingo card, he also pointed to Sanofi’s July 2025 acquisition of Vicebio for $1.6 billion, scooping up a combination vaccine for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). “Those things will launch 5, 6, 7, 8 years from now. And so we have to assume that there’ll be a new administration or two between now and then,” Hudson said. “We don’t know what their sensitivities will be, but it’s okay, as long as there’s some objectivity in the regulator.” Hudson hinted that there could be more deals to come in the vaccine space. Sanofi’s legacy vaccine sales fell 8% in the third quarter and Hudson is predicting similar “softness” in the quarters to come. Hudson reiterated that the sales decline can be pinned on the “misinformation that is going around.” He noted the rise in measles cases as people opt out of vaccines. “We think it will settle down and we’ll move through it,” Hudson said. Sanofi has not provided guidance for 2026 yet. Hudson also spoke to recent vaccine schedule updates and other antivaccine actions at the Department of Health and Human Services (HHS). The CEO suggested that people are capable of educating themselves when it comes to vaccines in partnership with their care providers. “The vast majority of people understand the benefit of vaccines and their lives and generations of their family have been protected that way,” Hudson said. “Not everybody looks to the top of the HHS to get people with their guidance on how to live their lives.” He continued: “So I think people should be respectful of all guidance given, but I think talking to their own healthcare professional is still probably the best thing to do.” Vaccines Pesky ‘Macro Factors’—aka RFK Jr.—Come for Vaccine Pharmas’ Wallets Following restricted vaccine approvals and changes to CDC immunization schedules, Merck, Pfizer, GSK and Sanofi are all suffering revenue hits to their vaccine programs. November 7, 2025 · 4 min read · Annalee Armstrong Read more The Next Moment Vicebio and Dynavax’s programs may be years out from FDA review, but Sanofi’s flu-COVID combo, licensed from Novavax, is not. Hudson expects regulatory review to happen in 2027 or 2028. That shot is “going to be the next moment, I think, for an acceleration on vaccine utilization,” Hudson said. The product will offer convenience with a one-and-done approach for both infectious diseases. And it will be the only non-mRNA COVID shot available in the U.S. for those who do not want to receive a shot featuring that technology. “We think people are still very vaccine literate. We think they understand the reactogenicity or the tolerability challenges of mRNA,” Hudson said. Those post-vaccine reactions may have been tolerated during the global pandemic, but that’s not the case anymore, the CEO explained. He expects Sanofi will garner the over-55 and over-65 markets, particularly as the combo can offer a high dose needed for older people, who are at higher risk of death from the flu. “While there may be debates on Facebook and other places, the over-65s, I think, are highly motivated to get protected,” Hudson said, “because they know they are the ones that are most vulnerable.”

VaccineAcquisitionmRNA

29 Dec 2025

·www.pharmaceutical-technology.com

Sanofi buys hep B vaccine maker for $2.2bn

Sanofi’s executive vice president of vaccines Thomas Triomphe said the deal “brings new option to our portfolio”. Image credit: Below the Sky via Shutterstock.com. Sanofi has agreed to acquire hepatitis B vaccine manufacturer Dynavax for an equity value of around $2.2bn, bolstering the former’s pipeline amid significant vaccine policy changes in the US. The transaction, for a price of $15.50 per share in cash, is expected to close in the first quarter of 2026. Through the deal, Sanofi will acquire Dynavax’s hepatitis B vaccine HEPLISAV-B. The product won approval in the US and Europe in 2017 and 2021, respectively. Sanofi does not currently have a hepatitis B vaccine in its portfolio. The French drugmaker previously won approval for a hepatitis B vaccine in a joint venture with MSD, though the latter company now commercialises the jab, which is known under the HBVaxPro and Recombivax HB brand names in Europe and the US, respectively. Heplisav-B is administered via a two-dose regimen delivered within one month, unlike GSK’s Engerix-B and MSD’s Recombivax HB. These rival products are given in three doses over six months. With the Dynavax acquisition, Sanofi is adding a strong revenue avenue for the virus that causes serious liver infection. HEPLISAV-B generated sales of $268.4m in 2024, with Dynavax forecasting net product revenue of between $305m and $325m for 2025. GlobalData forecasts HEPLISAV-B will reach $677m in annual sales in 2031. GlobalData is the parent company of Pharmaceutical Technology . GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence William Blair analyst Matt Phipps said: “While the deal value does come slightly below our net present value for Heplisav of $2.6bn, we believe the acquisition makes sense given growing regulatory concerns around vaccines and investor questions on management’s strategy for value creation.” Earlier in December, the US Centers for Disease and Prevention (CDC) changed its guidance to no longer recommend that all US newborns receive the hepatitis B vaccine. The significant policy changes have created volatility in the infectious disease vaccine sector, along with catalysing backlash from several medical bodies . The jewel in Dynavax’s pipeline is its shingles vaccine candidate, currently in a Phase I/II trial. In results announced in August 2025, the jab, dubbed Z-1018, demonstrated comparable efficacy to GSK’s blockbuster Shingrix – a product that dominates the shingles market. However, Z-1018 had fewer local and systemic post-injection reactions, which might give it a market advantage on tolerability. About one in three people in the US develop shingles at least once in their lives, according to the CDC. Shingrix generated £3.4bn globally for GSK in 2024, representing the size of the shingles market. Sanofi’s executive vice president of vaccines Thomas Triomphe said: “Dynavax’s marketed adult hepatitis B vaccine and shingles candidate bring new options to our portfolio and underscore our commitment to providing vaccine protection across the lifespan.” Phipps commented that: “Sanofi is a logical acquisition partner for Dynavax given the company has extensive vaccine capabilities but the portfolio does not have an adult hepatitis B or shingles programme.” Pharmaceutical Technology Excellence Awards - Nominations Closed Nominations are now closed for the Pharmaceutical Technology Excellence Awards . A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact. Excellence in Action Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing , Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines. Discover the Impact

VaccineDrug ApprovalAcquisitionClinical Result

100 Deals associated with Hepatitis B vaccine(GlaxoSmithKline Plc)

External Link

KEGG	Wiki	ATC	Drug Bank
D04432	-	J07BC01	DBSALT001978

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hepatitis B	United States	GlaxoSmithKline LLC	28 Aug 1989

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01311674 (CTgov)	Phase 3	Hepatitis B	141	hepatitis B vaccine (Schedule 1- Standard Dose Primary Vaccination Series)	zbajlaypyu(ggcqlwytjc) = ecxceuopzt uaeucqbowg (itoighpbyl, 3065.6) View more	-	17 Aug 2021
				hepatitis B vaccine (Schedule 2 - High Dose Primary Vaccination Series)	zbajlaypyu(ggcqlwytjc) = rbeaxwdleq uaeucqbowg (itoighpbyl, 1097.3) View more
NCT02003703 (Pubmed \| JAMA Netw Open)	Phase 3	HIV Infections	107	Hepatitis B Revaccination (High-dose HBV vaccination)	dzsteyvdbt(ixmpwhevba) = pydwbmnzhe nscsvfulel (nrhatthuyx ) View more	-	02 Aug 2021
				Hepatitis B Revaccination (Standard-dose HBV vaccination)	dzsteyvdbt(ixmpwhevba) = fqesohryxe nscsvfulel (nrhatthuyx ) View more
ECCO2021	Not Applicable	Inflammatory Bowel Diseases	104	Intra-dermal hepatitis B vaccination with topical imiquimod	vbjlxvuvmp(chtfpivnyw) = qrnerhsmgm fhzhlzlurq (gyvbjxxifd ) View more	Positive	02 Jul 2021
				Intra-muscular recombinant hepatitis B vaccine with topical aqueous cream	vbjlxvuvmp(chtfpivnyw) = snwnqwchxy fhzhlzlurq (gyvbjxxifd ) View more
NCT03393754 (PROTECT, EASL2020)	Phase 3	Hepatitis B	1,607	Engerix-B (Sci-B-Vac 10 Î¼g)	kfrfehmall(phlgeulnmp) = xhuiuqvxkt wufdxpytsw (oekbjtmdxz ) View more	Positive	27 Aug 2020
				Engerix B 20 Î¼g	kfrfehmall(phlgeulnmp) = tyhopjanvg wufdxpytsw (oekbjtmdxz ) View more
NCT02169674 (CTgov)	Phase 4	Hepatitis B	359	EngerixB, GlaxoSmithKline Vaccines (10-11 Year-olds)	wtcwznulkh = ohrzwmwnrw dumsmkqspm (jggnigjsvk, rwseuvpueq - vqjgzmkkyv) View more	-	21 Mar 2019
				EngerixB, GlaxoSmithKline Vaccines (15-16 Year-olds)	wtcwznulkh = jcxdjtowco dumsmkqspm (jggnigjsvk, okoyiudzyg - ykeuqlkubs) View more
NCT02798952 (CTgov)	Phase 4	Hepatitis B	302	Engerix-B Kinder+Infanrix hexa	jvhjlsknmk(bbisccsffa) = iqldvaymzf jkffjhsmtz (ftsqzkmzjj, kqwyftkhxi - xnqgtmnaht) View more	-	01 Feb 2019
ASN2018	Not Applicable	anti-HBsAg titer	28	Standard Double-Dose Intramuscular Vaccine	hibhwoeicx(enzgihrwri) = There were no reports of adverse events associated with intradermal dosing rebzkhyvaz (jsontsaevh )	Positive	23 Oct 2018
NCT02901951 (CTgov)	Phase 4	Hepatitis B	106	Engerix-B	wrlhraevow = hmuotsinip umoyqrzueu (osxutmhyph, gkapsnpshs - qxyemfiwhi) View more	-	03 Aug 2018
NCT01817725 (CTgov)	Phase 1	Hepatitis B, Chronic	20	HBV vaccine	wyqmqmlkjp(ssqmsckrpa) = ehkmymkbmv irfgxsyaii (ryudkmulzx, 0.48) View more	-	02 May 2017
NCT01847430 (Pubmed \| Vaccine)	Phase 4	Hepatitis B	303	Hepatitis B vaccine challenge dose	bxvjtxtdun(resnoxtvpp) = spqumkynew skiggqjcia (qncpqftqup, 94.2 - 98.6) View more	-	23 May 2016

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis